ArticleJournal of inflammation research2021
A Novel Modified-Curcumin Promotes Resolvin-Like Activity and Reduces Bone Loss in Diabetes-Induced Experimental Periodontitis.
Article in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Chemically modified curcumin in periodontal therapy: a scoping review.Evidence-based dentistry · 2026Article
- Systemic Bone Loss and Periodontal Disease: An Updated Review of a Bidirectional Association.Dentistry journal · 2026Review
- Inhibition of membrane RANKL production in osteoblasts mediates curcumin-inhibited osteoclastogenesis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- A novel modified-curcumin 2.24 suppresses MMPs in a periodontal-relevant cell culture model: a pilot study.Frontiers in oral health · 2026Article
- Molecular mechanisms and preclinical evidence of natural products in diabetic osteoporosis: a review.Frontiers in endocrinology · 2026Review
- Mitochondrial dysfunction as a key player in aggravating periodontitis among diabetic patients: review of the current scope of knowledge.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The research progress on periodontitis by the National Natural Science Foundation of China.International journal of oral science · 2025Review
- Targeting Epigenetic Plasticity to Reduce Periodontitis-Related Inflammation in Diabetes: CBD, Metformin, and Other Natural Products as Potential Synergistic Candidates for Regulation? A Narrative Review.International journal of molecular sciences · 2025Review
- Diabetes, periodontal disease, and novel therapeutic approaches- host modulation therapy.Frontiers in clinical diabetes and healthcare · 2025Review
- A novel modified-curcumin 2.24 resolves inflammation by promoting M2 macrophage polarization.Scientific reports · 2023Article
- Novel Hydrogenated Derivatives of Chemically Modified Curcumin CMC2.24 Are Potent Inhibitors of Melanogenesis in an In Vitro Model: Influence of Degree of Hydrogenation.Life (Basel, Switzerland) · 2023Article
- Diabetes mellitus promotes susceptibility to periodontitis-novel insight into the molecular mechanisms.Frontiers in endocrinology · 2023Review
- Protective effects of curcumin against osteoporosis and its molecular mechanisms: a recent review in preclinical trials.Frontiers in pharmacology · 2023Review
- Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss.Journal of inflammation research · 2023Article
- Host Response Modulation Therapy in the Diabetes Mellitus-Periodontitis Conjuncture: A Narrative Review.Pharmaceutics · 2022Review
- Dynamic changes in tooth displacement and bone morphometry induced by orthodontic force.Scientific reports · 2022Article
- Potential Therapeutic Applications of Natural Compounds in Diabetes-Associated Periodontitis.Journal of clinical medicine · 2022Review
- Curcumin Prevents Diabetic Osteoporosis through Promoting Osteogenesis and Angiogenesis Coupling via NF-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction.Frontiers in endocrinology · 2022Review
- HO-1 in Bone Biology: Potential Therapeutic Strategies for Osteoporosis.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeClinically, it is challenging to manage diabetic patients with periodontitis. Biochemically, both involve a wide range of inflammatory/collagenolytic conditions which exacerbate each other in a "bi-directional manner." However, standard treatments for this type of periodontitis rely on reducing the bacterial burden and less on controlling hyper-inflammation/excessive-collagenolysis. Thus, there is a crucial need for new therapeutic strategies to modulate this excessive host response and to promote enhanced resolution of inflammation. The aim of the current study is to evaluate the impact of a novel chemically-modified curcumin 2.24 (CMC2.24) on host inflammatory response in diabetic rats.
methodsType I diabetes was induced by streptozotocin injection; periodontal breakdown then results as a complication of uncontrolled hyperglycemia. Non-diabetic rats served as controls. CMC2.24, or the vehicle-alone, was administered by oral gavage daily for 3 weeks to the diabetics. Micro-CT was used to analyze morphometric changes and quantify bone loss. MMPs were analyzed by gelatin zymography. Cell function was examined by cell migration assay, and cytokines and resolvins were measured by ELISA.
resultsIn this severe inflammatory disease model, administration of the pleiotropic CMC2.24 was found to normalize the excessive accumulation and impaired chemotactic activity of macrophages in peritoneal exudates, significantly decrease MMP-9 and pro-inflammatory cytokines to near normal levels, and markedly increase resolvin D
conclusionIn conclusion, treating hyperglycemic diabetic rats with CMC2.24 (a tri-ketonic phenylaminocarbonyl curcumin) promotes the resolution of local and systemic inflammation, reduces bone loss, in addition to suppressing collagenolytic MMPs and pro-inflammatory cytokines, suggesting a novel therapeutic strategy for treating periodontitis complicated by other chronic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.